Venture Advanced Therapies, Ltd, 22 Lacey Drive, Edgware, Middlesex, HA8 8FZ, United Kingdom.
J Pharm Sci. 2021 May;110(5):1909-1914. doi: 10.1016/j.xphs.2021.02.006. Epub 2021 Feb 9.
The advent and rapid propagation of Chimeric Antigen Receptor (CAR)-based therapeutics in recent years has taken the oncology field by storm and delivered considerable benefit to cancer patients, many of whom previously had no other treatment options available to them. CAR-based therapies are now a bona fide therapeutic modality in the fight against cancer, along with more "traditional" treatments, such as small molecule and antibody drugs. For the technology to take the next step and reach much larger numbers of patients in need, it will be necessary for those treatments to become "off-the-shelf" offering patients a standardised, consistent, and cost-effective product. This article offers an overview of the evolution and development options for off-the-shelf CAR-based treatments, the advantages and disadvantages of the various approaches, along with key optimisation parameters that must be considered.
近年来，嵌合抗原受体（CAR）疗法的出现和快速传播席卷了肿瘤学领域，为许多以前没有其他治疗选择的癌症患者带来了显著的益处。CAR 疗法现在是对抗癌症的一种真正的治疗方式，与更“传统”的治疗方法（如小分子和抗体药物）一起。为了使该技术迈出下一步，为更多有需要的患者提供治疗，这些治疗方法必须成为“现成的”，为患者提供标准化、一致和具有成本效益的产品。本文概述了现成的 CAR 治疗方法的演变和发展选择，以及各种方法的优缺点，以及必须考虑的关键优化参数。
